Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bisoprolol + perindopril
- Development stage
- Unknown
- Lead developer
- Servier
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Bisoprolol + perindopril is a fixed-dose combination drug used primarily for the treatment of hypertension (high blood pressure), angina pectoris, and to reduce cardiovascular risk in patients with coronary artery disease or a history of myocardial infarction. Bisoprolol is a cardioselective beta-1 adrenergic receptor blocker that lowers heart rate, reduces cardiac output, and decreases blood pressure by antagonizing β1-adrenoceptors in the heart. Perindopril is an angiotensin-converting enzyme (ACE) inhibitor that prevents the conversion of angiotensin I to angiotensin II, leading to vasodilation and further reduction in blood pressure. The combination targets both sympathetic nervous system activity (via beta-blockade) and the renin–angiotensin–aldosterone system (via ACE inhibition), providing additive antihypertensive effects as well as benefits for patients with stable coronary artery disease or prior myocardial infarction[4][5][8].
- Brand names
- bisoprolol + perindopril
- Other names
- bisoprolol/perindoprilsingle-pill combination of bisoprolol and perindopril
02
Targets
ACE (Angiotensin Converting Enzyme)ADRB1 (β1)
Beyond the preview
Go deeper on bisoprolol + perindopril.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bisoprolol + perindopril.